Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer’s disease
Open accessAbstract
While neuritic plaques and neurofibrillary tangles in older adults are correlated with cognitive impairment and severity of dementia, it has long been recognized that the relationship is imperfect as some people exhibit normal cognition despite high levels of AD pathology. We compared the cellular, synaptic and biochemical composition of midfrontal cortices in female subjects from the Religious Orders Study who were stratified into three subgroups: 1) pathological AD with normal cognition (“AD-Resilient”), 2) pathological AD with AD-typical dementia (“AD-Dementia)” and 3) pathologically normal with normal cognition (“Normal Comparison”). The AD-Resilient group exhibited preserved densities of synaptophysin-labeled presynaptic terminals and synaptopodin-labeled dendritic spines compared to the AD-Dementia group, and increased densities of GFAP astrocytes compared to both the AD-Dementia and Normal Comparison group. Further, in a discovery antibody microarray protein analysis we identified a number of candidate protein abnormalities that were associated with diagnostic group. These data characterize cellular and synaptic features and identify novel biochemical targets that may be associated with resilient cognitive brain aging in the setting of pathological AD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 31 cited sources checked · 0 supported · 0 flagged
- Findingown data
GFAP astrocyte densities differed among groups, with post-hoc tests showing increased density in the AD-Resilient group compared to both AD-Dementia and Normal Comparison groups.
“GFAP astrocyte densities differed among groups with post-hoc tests demonstrating increased density in the AD-Resilient group compared to both the AD-Dementia and NC groups.”
- Also stated in: § Abstract · plain
“increased densities of GFAP astrocytes compared to both the AD-Dementia and Normal Comparison group.”
Quote in the paperSubstantial claim - Also stated in: § Abstract · plain
- Findingown data
PHFtau neurofibrillary tangles negatively correlated with synaptopodin spines (ρ=−0.45, p=0.01).
“negatively correlated with synaptopodin spines (ρ=−0.45, p=0.01)”
Quote in the paperNot a substantial claim - Findingown data
One-way ANOVA identified 57 proteins that distinguished the groups.
“Using one-way ANOVA, we then identified 57 proteins that distinguished the groups (Table 3), and visualized the proteins in a heat map (Figure 2b).”
Quote in the paperSubstantial claim - Findingown data
Pre- and postsynaptic measures were highly correlated (Spearman's r = 0.58, p = 0.0009).
“In accord with their expected relationship, pre- and postsynaptic measures were highly correlated (Spearman’s r = 0.58, p = 0.0009).”
Quote in the paperNot a substantial claim - Findingown data
Amyloid-β plaques negatively correlated with synaptopodin spines (ρ=−0.44, p=0.02).
“negatively correlated with synaptopodin spines (ρ=−0.44, p=0.02)”
Quote in the paperSubstantial claim
- Findingown data
Principal components analysis showed tight clustering of Normal Comparison cases while AD-Dementia and AD-Resilient cases were more dispersed.
“With PCA we observed tight clustering of NC cases while AD-Dementia and AD-Resilient cases were more dispersed (Figure 2a).”
Quote in the paperSubstantial claim - Findingown data
The AD-Dementia group had lower synaptopodin spine and synaptophysin measures than both AD-Resilient and Normal Comparison groups.
“The AD-Dementia group exhibited lower measures compared to both AD-Resilient and NC groups.”
- Also stated in: § Abstract · plain
“The AD-Resilient group exhibited preserved densities of synaptophysin-labeled presynaptic terminals and synaptopodin-labeled dendritic spines compared to the AD-Dementia group”
Quote in the paperSubstantial claim - Also stated in: § Abstract · plain
- Findingown data
Post-hoc comparisons identified 16 proteins that significantly differentiated AD-Resilient and AD-Dementia groups.
“Post-hoc comparisons identified 16 proteins that significantly differentiated AD-Resilient and AD-Dementia groups (Table 3).”
Quote in the paperSubstantial claim - Findingown data
Amyloid-β plaques negatively correlated with NeuN neurons (ρ=−0.39, p=0.03).
“They negatively correlated with NeuN neurons (ρ=−0.39, p=0.03)”
Quote in the paperNot a substantial claim - Findingown data
Amyloid-β plaques positively correlated with GFAP astrocytes (ρ=0.49, p=0.008).
“positively correlated with GFAP astrocytes (ρ=0.49, p=0.008)”
Quote in the paperNot a substantial claim - Findingown data
PHFtau neurofibrillary tangles positively correlated with GFAP astrocytes (ρ=0.43, p=0.03).
“PHFtau neurofibrillary tangles were positively correlated with GFAP astrocytes (ρ=0.43, p=0.03)”
Quote in the paperNot a substantial claim - Findingown data
GFAP astrocytes were increased in the AD-Resilient group compared to both the AD-Dementia and NC groups.
“We found that GFAP astrocytes were increased in the AD-Resilient group compared to both the AD-Dementia and NC groups.”
Quote in the paperSubstantial claim - Findingown data
The three groups did not differ significantly in NeuN neuron densities.
“The three groups did not differ significantly in NeuN neuron densities.”
Quote in the paperSubstantial claim - Findingown data
The antibody microarray analysis identified candidate protein abnormalities associated with diagnostic group.
“Further, in a discovery antibody microarray protein analysis we identified a number of candidate protein abnormalities that were associated with diagnostic group.”
Quote in the paperSubstantial claim- Rests on an assumption: The 507 proteins measured by the Clontech antibody microarray include proteins relevant to resilient cognition in Alzheimer’s disease.
- Findingown data
The synaptopodin and synaptophysin measures were strongly correlated.
“The postsynaptic synaptopodin and presynaptic synaptophysin measures were highly correlated”
Quote in the paperSubstantial claim - Findingown data
Certain proteins differentiated the AD-Resilient group from the AD-Dementia group.
“Nonetheless, we identified some proteins that distinguished the AD-Resilient group from the AD-Dementia group.”
Quote in the paperSubstantial claim- Rests on an assumption: The differentially expressed proteins identified by the antibody microarray are not false positives arising from multiple comparisons.
- Findingown data
Proteins involved in apoptosis regulation were differentially expressed, including interleukin-3, tumor necrosis factor receptor, and transcription factor 3 (E2α), along with others related to intracellular trafficking, cytoskeleton, transcription, and cell cycle.
“Several proteins that mediate or regulate apoptosis were also differentially expressed, including interleukin-3, tumor necrosis factor receptor, and transcription factor 3 (E2α), as well as other proteins with intracellular trafficking, cytoskeletal, transcriptional and cell cycle regulation.”
Quote in the paperNot a substantial claim- Rests on an assumption: The differentially expressed proteins identified by the antibody microarray are not false positives arising from multiple comparisons.
- Findingown data
Between AD-Resilient and AD-Dementia groups, a difference was observed in amyloid-β precursor binding protein.
“Differences were seen in amyloid-β precursor binding protein (which inhibits production of proteolytic APP fragments and protects against memory loss in AD transgenic mouse models (Mitchell, et al., 2010))”
Quote in the paperSubstantial claim- Rests on an assumption: The differentially expressed proteins identified by the antibody microarray are not false positives arising from multiple comparisons.
- Premisecitation
Some individuals have normal cognition despite high levels of Alzheimer's disease pathology.
“Normal cognition despite pathological AD was recognized over 80 years ago and has been described in case reports and series (Terry, et al., 1991,Tomlinson, et al., 1968).”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
The Nun Study found discordance between cognition and pathology.
“For example, the Nun Study has shown discordance of cognition with pathology as well as the important effects of education, diet, linguistic ability, and childhood positive emotion on cognitive function in late life (Iacono, et al., 2009,Tyas, et al., 2007).”
Quote in the paperSubstantial claim0 of 2 sources checked - Interpretationown data
Healthy cognition occurs across a spectrum of brain pathology, from cognitively intact individuals with relatively little pathology to resilient individuals with significant pathology.
“While such cases may be the minority, it is evident that healthy cognition occurs amidst a spectrum of brain pathology - from those who remain cognitively intact and whose brains are relatively free of neurodegenerative disease or other pathological lesions to those who remain resilient even with significant accumulations of pathology.”
Quote in the paperSubstantial claim - Premisecitation
The Baltimore Longitudinal Study of Aging, Honolulu-Asia Aging Study, and MRC-CFAS reported dissociations between plaques, tangles or other pathological lesions and cognition.
“The Baltimore Longitudinal Study of Aging (O’Brien, et al., 2009), the Honolulu-Asia Aging Study (White, 2009), and the MRC-CFAS (Savva, et al., 2009) have similarly reported dissociations between plaques, tangles or other pathological lesions and cognition.”
Quote in the paperSubstantial claim0 of 3 sources checked - Premisecitation
In the Religious Orders Study and Rush Memory and Aging Project, about one third of older people with normal cognition have plaque and tangle densities meeting NIA-Reagan criteria for intermediate or high likelihood of Alzheimer's disease, as well as infarctions and Lewy bodies.
“In the Religious Orders Study (ROS) and its companion study, the Rush Memory and Aging Project (MAP)(Bennett, 2006), we have found that a third of older people with normal cognition have densities of plaques and tangles that meet NIA-Reagan criteria for intermediate or even high likelihood of AD, as well as infarctions and Lewy bodies (Bennett, et al., 2006b,Schneider, et al., 2007).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites Bennett, et al., 2006b
Not checked in the free run.
- cites Schneider, et al., 2007 source
Not checked in the free run.
- Premisecitation
The poor correlation between pathology and cognition may be more pronounced in the oldest-old.
“This relatively poor correlation may become even more pronounced in the oldest-old (Ewbank and Arnold, 2009,Haroutunian, et al., 2008).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites Ewbank and Arnold, 2009
Not checked in the free run.
- cites Haroutunian, et al., 2008 source
Not checked in the free run.
- Study design and conductown data
Analyses of main outcome variables including or excluding cases with rare Lewy bodies or hippocampal sclerosis did not differ.
“Results from analyses of the main outcome variables of interest including or excluding these cases did not differ.”
Quote in the paperNot a substantial claim - Study design and conductown data
No significant associations were observed between NeuN, GFAP, synaptopodin spine, and synaptophysin density measures and age, education, antemortem interval, postmortem interval, hemisphere used, or exposure to potentially relevant medications, within the whole cohort or within each diagnostic category.
“We observed no significant associations of the anatomical variables with any of these potential confounds (Supplement Table).”
Quote in the paperNot a substantial claim - Interpretationown data
Preserved connectivity is indicated by normal synaptophysin expression in the AD-Resilient group.
“normal synaptophysin expression in midfrontal cortex in the AD-Resilient group indicates preserved connectivity”
Quote in the paperSubstantial claim - Premisecitation
Few studies have described cellular or molecular correlates of resilient brain aging.
“There have been relatively few reports describing cellular or molecular correlates of resilient brain aging.”
Quote in the paperNot a substantial claim0 of 3 sources checked - Interpretationown data
The lack of difference in NeuN neuron densities suggests no gross neuron loss in the mid-frontal cortex across the groups.
“While this finding suggests no gross neuron loss in the mid-frontal cortex across these groups”
Quote in the paperSubstantial claim - Study design and conductreasoning
Density may not reflect total neuron number because reduction in the reference area or volume used to calculate density due to atrophy would attenuate differences.
“we recognize that density may not reflect total number because reduction in the reference area/volume used to calculate density due to atrophy would attenuate differences.”
Quote in the paperNot a substantial claim - Premisecitation
Synaptopodin is a robust marker of dendritic spines.
“We found that synaptopodin, an actin-associated protein enriched in postsynaptic densities is a robust marker of dendritic spines (Soetanto, et al., 2010).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Soetanto, et al., 2010 source
Not checked in the free run.
- Interpretationown data
Decreased connectivity is suggested by reduced synaptophysin expression in the AD-Dementia group.
“the reduced synaptophysin expression in the AD-Dementia group suggests decreased connectivity.”
Quote in the paperSubstantial claim - Interpretationown data
The correlation between these markers mutually confirms synaptic preservation in the AD-Resilient group.
“thus providing mutual confirmation of synaptic preservation in the AD-Resilient group.”
Quote in the paperSubstantial claim - Study design and conductreasoning
Generalizability to other populations may be limited.
“However, generalizability to other populations may be limited.”
Quote in the paperNot a substantial claim - Study design and conductreasoning
The ROS cohort is well-suited because its participants are relatively uniform in education, nutrition, healthcare, culture, and lifestyle, factors that if more varied could confound a neurobiological study of resilience.
“In many ways, the ROS is an ideal cohort for this given its participants’ relatively uniform education, nutrition, healthcare, cultural and other lifestyle factors that if more diverse, might confound a neurobiological study of resilience.”
Quote in the paperSubstantial claim - Study design and conductnone given
The sample stratification maximized contrast between AD-Resilient and AD-Dementia groups for the target features (pathology × cognition).
“Our sample stratification served to maximize contrast of AD-Resilient and AD-Dementia groups for the target features of interest (pathology × cognition).”
Quote in the paperSubstantial claim - Interpretationown data
Resilient brain aging can be distinguished cellularly and biochemically.
“It nonetheless remains noteworthy that resilient brain aging can be distinguished cellularly and biochemically”
Quote in the paperSubstantial claim- Rests on an assumption: The observed cellular and biochemical differences between the AD-Resilient group and the other groups are not attributable to confounds such as agonal state or postmortem changes.
- Rests on an assumption: The differentially expressed proteins identified by the antibody microarray are not false positives arising from multiple comparisons.
- May combine two claims. 23
- Classified as probably not a substantial claim. 23
- The quote only partly states this claim. 2
May combine two claims.
Findingown dataBoth synaptopodin spines and synaptophysin immunoexpression were preserved in the AD-Resilient group, with levels comparable to the Normal Comparison group.
“Both synaptopodin spines and synaptophysin immunoexpression were preserved in AD-Resilient group, with levels comparable to those in the NC group.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingown dataPHFtau tangles negatively correlated with NeuN neurons (ρ=−0.31, p=0.10), but this was not statistically significant.
“Whjle not statistically significant, PHFtau tangles negatively correlated with NeuN neurons (ρ=−0.31, p=0.10)”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataThe Normal Comparison group was especially distinct from AD-Dementia and AD-Resilient groups, but some differentiation in expression pattern between AD-Dementia and AD-Resilient groups was observed.
“The NC group was especially distinct from AD-Dementia and AD-Resilient groups, but we did observe some differentiation in the expression pattern between AD-Dementia and AD-Resilient groups.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingown dataPHFtau tangles negatively correlated with synaptophysin (ρ=−0.27, p=0.16), but this was not statistically significant.
“and synaptophysin (ρ=−0.27, p=0.16).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingown dataBrain weights were lower in the AD-Dementia group than in the AD-Resilient and Normal Comparison groups, but the differences were not statistically significant.
“Brain weights were less in the AD-Dementia group compared to the AD-Resilient and NC groups but differences were not statistically significant (Table 1 and Supplement Figure).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataAmyloid-β plaque percent areas and PHFtau neurofibrillary tangle densities in midfrontal cortex were comparable in AD-Resilient and AD-Dementia groups, and both were significantly greater than in the Normal Comparison group.
“Immunohistochemically labeled amyloid-β plaque % areas and PHFtau neurofibrillary tangle densities in midfrontal cortex were comparable in the AD-Resilient and AD-Dementia groups and both were significantly greater in these groups than the NC group.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataSignificant differences were found among groups in apolipoprotein E ε4 allele frequency, mini-mental state examination score, and CERAD and Braak scores.
“As expected, significant differences were found in frequency of apolipoprotein E ε4 allele, mini-mental state examination score, and CERAD and Braak scores.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingown dataNeuN neuron density was slightly lower in the Normal Comparison group than in both AD-Resilient and AD-Dementia groups, but the differences were not significant.
“NeuN neuron density was slightly lower in the NC group compared to both the AD-Resilient and AD-Dementia groups, but differences were not significant.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataSynaptophysin expression was normal in midfrontal cortex in the AD-Resilient group and reduced in the AD-Dementia group.
“normal synaptophysin expression in midfrontal cortex in the AD-Resilient group indicates preserved connectivity while the reduced synaptophysin expression in the AD-Dementia group suggests decreased connectivity.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataPCA showed tight clustering of component scores for NC cases, whereas AD cases (both AD-Dementia and AD-Resilient) had more variable distributions.
“It is noteworthy that PCA found tight clustering of component scores of the NC cases while the cases with pathological AD, both AD-Dementia and AD-Resilient, were more variable in their distributions.”
Quote in the paperNot a substantial claimThe quote only partly states this claim.
Findingown dataBetween AD-Resilient and AD-Dementia groups, a difference was observed in serine/threonine-protein phosphatase (PP2A).
“serine/threonine-protein phosphatase (“PP2A”, an important phosphatase for tau (Iqbal, et al., 2009))”
Quote in the paperSubstantial claim- Rests on an assumption: The differentially expressed proteins identified by the antibody microarray are not false positives arising from multiple comparisons.
May combine two claims.
Findingown dataDensity of synaptopodin-labeled spine puncta was lower in AD-Dementia and similar to normal in AD-Resilient.
“We found synaptopodin-labeled spine puncta density to be reduced in AD-Dementia as well, but densities were equivalent to normal in the AD-Resilient group.”
Quote in the paperSubstantial claimThe quote only partly states this claim.
Findingown dataBetween AD-Resilient and AD-Dementia groups, a difference was observed in lymphocyte-specific protein tyrosine kinase.
“lymphocyte-specific protein tyrosine kinase (which phosphorylates tyrosine residues in tau, has been reported to be decreased in AD and genetically associated with AD (Scales, et al., 2011))”
Quote in the paperSubstantial claim- Rests on an assumption: The differentially expressed proteins identified by the antibody microarray are not false positives arising from multiple comparisons.
Classified as probably not a substantial claim. May combine two claims.
PremisecitationAmyloid-β plaques and hyperphosphorylated tau tangles are common age-related lesions that are presumed to play primary pathophysiological roles in Alzheimer's disease dementia.
“Amyloid-β plaques and hyperphosphorylated tau neurofibrillary tangles are common age-related lesions that are presumed to play primary pathophysiological roles in the dementia of Alzheimer’s disease (AD)(Jellinger, 2009).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Jellinger, 2009 source
Not checked in the free run.
May combine two claims.
PremisecitationThe Nun Study found that education, diet, linguistic ability, and childhood positive emotion affect late-life cognitive function.
“For example, the Nun Study has shown discordance of cognition with pathology as well as the important effects of education, diet, linguistic ability, and childhood positive emotion on cognitive function in late life (Iacono, et al., 2009,Tyas, et al., 2007).”
Quote in the paperNot a substantial claim0 of 2 sources checkedClassified as probably not a substantial claim.
Study design and conductnone givenTen cases from each group were filtered to be most closely matched for age and postmortem interval.
“We then filtered 10 cases from each group that were most closely matched for age and postmortem interval.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Study design and conductnone givenCases with clinical or pathological diagnoses other than normal, mild cognitive impairment, or Alzheimer's disease that could contribute to cognitive impairment were excluded.
“We excluded any cases with clinical or pathological diagnoses other than normal, MCI or AD that potentially contributed to cognitive impairment (e.g., abundant Lewy body pathology, infarcts, hippocampal sclerosis, etc.).”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationIndependent publications report very high validity of differential protein expression on the Clontech antibody array, verified with Western blotting, and our preliminary findings were consistent with this.
“Independent publications report very high validity of differential protein expression, verified with Western blotting, and our preliminary study findings were consistent with this.”
Quote in the paperSubstantial claim0 of 2 sources checkedClassified as probably not a substantial claim.
Study design and conductcitationNeuropathologic diagnoses of Alzheimer's disease were made by a board-certified neuropathologist blinded to age and all clinical data using NIA-Reagan, Braak, and CERAD classifications.
“Neuropathologic diagnoses of AD were established by a board-certified neuropathologist blinded to age and all clinical data according to NIA-Reagan (Hyman and Trojanowski, 1997), Braak (Braak and Braak, 1995), and CERAD (Mirra, et al., 1991) classifications.”
Quote in the paperSubstantial claim0 of 3 sources checkedClassified as probably not a substantial claim.
PremisecitationThe midfrontal gyrus cortex was chosen because of its important role in complex cognition and its common neuropathological involvement in Alzheimer's disease.
“The midfrontal gyrus cortex (corresponding predominantly to Brodmann area 46) was chosen for semi-quantitative image analyses of AD pathology, cellular and synaptic markers because of its important role in complex cognition and its common neuropathological involvement in the spectrum of AD (Arnold, et al., 1991).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Arnold, et al., 1991 source
Not checked in the free run.
Classified as probably not a substantial claim.
Study design and conductnone givenSelected cases were inspected for other clinical data that might skew the pathology-cognition relationship, and alternative cases were substituted as necessary.
“Finally, we inspected the selected cases for other clinical data that might skew the relationship between pathology and cognition, i.e., unusual medical or psychiatric conditions, medicines, or causes of death, and substituted alternative cases as necessary.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductcitationClinical evaluations in the Religious Orders Study were performed by personnel blinded to previous evaluations.
“Annual evaluations included a uniform structured interview and examination consisting of medical history, neurological examination and cognitive testing by trained personnel who are blind to previous evaluations, as previously described (Bennett, et al., 2002).”
- Also stated in: § 2.1 Case Materials · plain
“Follow-up evaluations, identical in all essential details, were performed annually by examiners blinded to previously collected data.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Bennett, et al., 2002 source
Not checked in the free run.
- Also stated in: § 2.1 Case Materials · plain
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenImage acquisition and analyses were conducted masked to case information.
“All image acquisition and analyses were conducted masked to case information.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenData were collected in single sections that were all stained in single runs with uniform development times.
“Data was collected in single sections that were all stained in single runs with uniform development times.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenThe hemisphere used for diagnostic and frozen blocks alternated randomly between cases.
“The hemisphere used for diagnostic and frozen blocks alternated randomly between cases.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe Clontech antibody array has been used in a variety of settings since 2003.
“The Clontech antibody array has been used in a variety of settings since 2003 (Anderson, et al., 2003,Hatjiharissi, et al., 2007).”
Quote in the paperNot a substantial claim0 of 2 sources checkedClassified as probably not a substantial claim.
Study design and conductreasoningSelection was limited to female participants to minimize sex and major lifestyle differences.
“We first limited our selection to female participants in the ROS cohort, thus minimizing sex and major lifestyle differences (given relatively similar lifestyles activities, diet, habits and healthcare of Catholic female clergy).”
Quote in the paperSubstantial claimMay combine two claims.
Study design and conductown dataStatistical analyses showed no significant differences among groups for education, hormone replacement therapy use, postmortem interval, brain weight, and presence or absence of macroscopic or microscopic infarcts.
“Statistical analyses further showed no significant differences among groups for education, use of hormone replacement therapy (only 1 normal comparison case had ever been on this), postmortem interval, brain weight, and presence or absence of macroscopic or microscopic infarcts, which if present, were in regions other than mid-frontal cortex.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataThe protein expression profile of healthy brain tissue is distinct from that of tissue with abundant Alzheimer's disease pathology, and Alzheimer's disease pathology disrupts protein expression in non-cohesive ways.
“This suggests that the protein expression profile of healthy brain tissues is distinct from those with abundant AD pathology and that AD pathology disrupts protein expression in non-cohesive ways.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataPreliminary microarray experiments showed an average coefficient of variation of 0.14 (SD=0.27, range 0.01 to 2.0) for protein measurements.
“Preliminary experiments with the microarray were conducted to examine the inter-experiment reliability of the platform. Aliquots of pooled tissue homogenates from two groups were run in four separate experiments and coefficient of variations (CV) were calculated for each of the protein measurements on the array. Average CV was 0.14 (SD=0.27, range 0.01 to 2.0)”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationSynaptic loss is often considered the strongest neuropathological correlate of dementia severity in Alzheimer's disease and is linked to amyloid-β and tau pathology.
“Synaptic loss is frequently cited as the best neuropathological correlate of dementia severity in AD (Terry, et al., 1991) and has been linked to the accumulation of both amyloid-β and tau pathology (Arendt, 2009).”
Quote in the paperSubstantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationCortical astrocytes support brain health through structural, biochemical, and regulatory functions, including ion balance, nutrient supply, blood flow regulation, transmitter uptake and release, synaptic modulation, and trophic and detoxifying support.
“Cortical astrocytes maintain brain health through structural and biochemical support to neurons and endothelial cells, maintain extracellular ion balance, provide nutrients to neurons, regulate cortical blood flow, transmitter uptake and release, modulate synaptic neurotransmission and provide trophic and detoxifying support in response to injury (Sofroniew and Vinters, 2010).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Sofroniew and Vinters, 2010 source
Not checked in the free run.
May combine two claims.
Interpretationown dataThese data characterize cellular and synaptic features and identify novel biochemical targets that may be associated with resilient cognitive brain aging in the setting of pathological Alzheimer's disease.
“These data characterize cellular and synaptic features and identify novel biochemical targets that may be associated with resilient cognitive brain aging in the setting of pathological AD.”
Quote in the paperSubstantial claim- Rests on an assumption: The 507 proteins measured by the Clontech antibody microarray include proteins relevant to resilient cognition in Alzheimer’s disease.
May combine two claims.
PremisecitationIn preclinical Alzheimer's disease cases, there is no measurable cognitive impairment per se, but cognitive function is degraded in the presence of plaques and tangles.
“Supporting this notion, Price et al. reported no measureable cognitive impairment per se in such preclinical AD cases, but degraded cognitive function in the presence of plaques and tangles (Price, et al., 2009).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Price, et al., 2009 source
Not checked in the free run.
Classified as probably not a substantial claim.
Study design and conductnone givenAn antibody microarray provided an unbiased measurement of relative expression for more than 500 proteins across diverse functional groups.
“An antibody microarray served as an unbiased measure of the relative expression levels of over 500 proteins that span a broad range of functional groups.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductreasoningThese methods could introduce systematic inaccuracies that reference volume-based stereology might avoid.
“However, they may introduce systematic inaccuracies that might be obviated with reference volume-based stereological approaches.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenMultiple comparisons remain a challenge, particularly with small sample sizes.
“but the challenge of multiple comparisons remains, especially in relatively small sample sizes.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenPostmortem neuropathology provides only a near-death snapshot, can suggest but not establish causal links between clinical and brain data, and confounds like agonal state and postmortem changes can alter cellular and molecular integrity.
“while postmortem neuropathology remains the best approach to investigate the neurobiology of uniquely human brain diseases, it only allows a snapshot of the brain as it was near the time of death, it can suggest, but not establish, causal relationships between clinical and brain data, and confounds such as agonal state and postmortem changes can alter the brains’ cellular and molecular integrity.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenUsing a pooled tissue standard, dye swapping, and calculated INR reduced many potential pitfalls.
“Our use of a pooled tissue standard as a reference in all experiments, dye swapping and calculated INR attenuated many potential pitfalls”
Quote in the paperNot a substantial claimMay combine two claims.
Study design and conductreasoningAutomated computer-assisted analyses reduce operator bias, are suitable for larger high-throughput studies, and successfully detected between-group differences.
“These minimize operator bias, lend themselves well to larger scale, high-throughput studies, and they successfully found between group differences.”
Quote in the paperNot a substantial claim
The paper relies on this without support.
There has been little postmortem investigation of neurobiological factors that might confer or be associated with resilient brain aging.
“Aside from noting such discordance in clinicopathological studies, there has been little pursuant postmortem investigation of neurobiological factors that might confer or be associated with resilient brain aging.”
The paper relies on this without support.
The correlation between Alzheimer’s disease neuropathological lesions and cognition is modest and accounts for limited variance among older adults.
“However, it is also recognized that the correlation between these neuropathological lesions and cognition is modest and accounts for a limited amount of the variance of cognition among older adults.”
The paper relies on this without support.
The 507 proteins measured by the Clontech antibody microarray include proteins relevant to resilient cognition in Alzheimer’s disease.
“The Clontech. Antibody Microarray 500 (Clontech, Mountainview, CA) was used to profile relative expression levels of 507 proteins.”
The paper relies on this without support.
Composite cognition scores from the last assessment before death accurately reflect the participants’ cognitive status relevant to group classification.
“We next stratified according to composite cognition scores from the last assessment before death and global pathology (average plaque and tangle burdens in diagnostic blocks).”
The paper relies on this without support.
The observed cellular and biochemical differences between the AD-Resilient group and the other groups are not attributable to confounds such as agonal state or postmortem changes.
“confounds such as agonal state and postmortem changes can alter the brains’ cellular and molecular integrity.”
The paper relies on this without support.
The differentially expressed proteins identified by the antibody microarray are not false positives arising from multiple comparisons.
“the challenge of multiple comparisons remains, especially in relatively small sample sizes.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some studies have reported preserved neuronal numbers and synaptic densities in the hippocampus in "preclinical/resilient AD" compared with normal and clinical AD cases.
“Some studies have reported preserved neuronal numbers and synaptic densities in the hippocampus in “preclinical/resilient AD” compared with normal and clinical AD cases [62], [108], [109].”
From Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease (2014) · cites this paper as [62]
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,841 · see citing works
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 12,617 · see citing works
limma: Linear Models for Microarray Data
Smyth, G. K. (2005) · Statistics for Biology and Health · doi:10.1007/0-387-29362-0_23 · Cited by 5,796 · see citing works
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196 · see citing works
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · see citing works
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · see citing works
Bioinformatics and Computational Biology Solutions Using R and Bioconductor
Gentleman, R. C., Carey, V. J., Huber, W. K., Irizarry, R. A., & Dudoit, S. (2005) · Statistics in the health sciences · doi:10.1007/0-387-29362-0 · Cited by 3,470 · see citing works
Java Treeview—extensible visualization of microarray data
Saldanha, A. J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth349 · Cited by 2,991 · see citing works
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859 · see citing works
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357 · see citing works
Observations on the brains of demented old people
Tomlinson, B. E., Blessed, G., & Roth, M. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90063-8 · Cited by 2,084 · see citing works
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992 · see citing works
Self-citationHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542 · see citing works
Alzheimer’s Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowski, J. Q., Toga, A. W., & Beckett, L. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-72076-0_18 · Cited by 1,493 · see citing works
Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & Van Hoesen, G. W. (1991) · Cerebral Cortex · doi:10.1093/cercor/1.1.103 · Cited by 1,380 · see citing works
Self-citationNeuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · see citing works
Self-citationParticipation in Cognitively Stimulating Activities and Risk of Incident Alzheimer Disease
Wilson, R. S. (2002) · JAMA · doi:10.1001/jama.287.6.742 · Cited by 1,312 · see citing works
Self-citationNatural history of mild cognitive impairment in older persons
Bennett, D. A., Wilson, R. S., Schneider, J. A., Evans, D. A., Beckett, L. A., Aggarwal, N. T., Barnes, L. L., Fox, J. H., & Bach, J. (2002) · Neurology · doi:10.1212/wnl.59.2.198 · Cited by 1,037 · see citing works
Self-citationThe Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Liu, E., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,011 · see citing works
Mandelkow, E., & Mandelkow, E. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01368-3 · Cited by 951 · see citing works
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900 · see citing works
DeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686 · see citing works
Self-citationObservations on the brains of non-demented old people
Tomlinson, B. E., Blessed, G., & Roth, M. (1968) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(68)90154-8 · Cited by 681 · see citing works
Mild Cognitive Impairment: An Overview
Petersen, R. C., & Negash, S. (2008) · CNS Spectrums · doi:10.1017/s1092852900016151 · Cited by 665 · see citing works
Self-citationNeuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · see citing works
Identification of normal and pathological aging in prospectively studied nondemented elderly humans
Dickson, D. W., Crystal, H. A., Mattiace, L. A., Masur, D. M., Blau, A. D., Davies, P., Yen, S.-H., & Aronson, M. K. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90027-u · Cited by 643 · see citing works
Anatomical and Physiological Plasticity of Dendritic Spines
Alvarez, V. A., & Sabatini, B. L. (2007) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094222 · Cited by 629 · see citing works
Mechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628 · see citing works
SZE, C.-I., TRONCOSO, J. C., KAWAS, C., MOUTION, P., PRICE, D. L., & MARTIN, L. J. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199708000-00011 · Cited by 562 · cited 1× · see citing works
“Other studies in the BLSA suggested intermediate changes in some presynaptic proteins, but not others, in preclinical or “early” AD (Sze et al., 1997; O’Brien et al., 2009).”
ResultBennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L., & Arnold, S. E. (2004) · Archives of Neurology · doi:10.1001/archneur.61.3.378 · Cited by 526 · see citing works
Self-citationSynaptic degeneration in Alzheimer's disease
Arendt, T. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0536-x · Cited by 517 · see citing works
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Liu, E., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.09.172 · Cited by 477 · see citing works
Bennett, D. A., Schneider, J. A., Aggarwal, N. T., Arvanitakis, Z., Shah, R. C., Kelly, J. F., Fox, J. H., Cochran, E. J., Arends, D., Treinkman, A., et al. (2006) · Neuroepidemiology · doi:10.1159/000096129 · Cited by 407 · see citing works
Self-citationMicroinfarct Pathology, Dementia, and Cognitive Systems
Arvanitakis, Z., Leurgans, S. E., Barnes, L. L., Bennett, D. A., & Schneider, J. A. (2011) · Stroke · doi:10.1161/strokeaha.110.595082 · Cited by 404 · see citing works
Self-citationDifferential loss of synaptic proteins in Alzheimer's disease: Implications for synaptic dysfunction
Reddy, P. H., Mani, G., Park, B. S., Jacques, J., MURDOCH, G. H., Whetsell, W. O., Kaye, J. A., & Mańczak, M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-7203 · Cited by 372 · see citing works
“Preclinical” AD revisited: Neuropathology of cognitively normal older adults
Schmitt, F. A., Davis, D. G., Wekstein, D. R., Smith, C. D., Ashford, J. W., & Markesbery, W. R. (2000) · Neurology · doi:10.1212/wnl.55.3.370 · Cited by 369 · see citing works
Hippocampal neurons in pre-clinical Alzheimer's disease.
West, M. J., Kawas, C. H., Stewart, W. F., Rudow, G. L., & Troncoso, J. C. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.005 · Cited by 317 · cited 2× · see citing works
“In contrast to the aforementioned studies, which described similarities between resilient/preclinical AD and AD with dementia, Troncoso and colleagues have reported differences, including preserved numbers and larger neuronal sizes in the hippocampus and other brain regions in “asymptomatic AD” cases compared with nor…”
ResultRecent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274 · see citing works
Entorhinal Cortex β-Amyloid Load in Individuals with Mild Cognitive Impairment
Mufson, E. J., Chen, E.-Y., Cochran, E. J., Beckett, L. A., Bennett, D. A., & Kordower, J. H. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7086 · Cited by 237 · see citing works
Self-citationIacono (2009) · doi:10.1212/wnl.0b013e3181b01077 · Cited by 203 · see citing works
White, L. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1178 · Cited by 193 · see citing works
Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease
Bradley, M. A., Markesbery, W. R., & Lovell, M. A. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.02.016 · Cited by 193 · see citing works
Neuronal Hypertrophy in Asymptomatic Alzheimer Disease
Iacono, D., O'Brien, R., Resnick, S. M., Zonderman, A. B., Pletnikova, O., Rudow, G., An, Y., West, M. J., Crain, B., & Troncoso, J. C. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181772794 · Cited by 188 · see citing works
Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study
Tyas, S. L., Salazar, J. C., Snowdon, D. A., Desrosiers, M. F., Riley, K. P., Mendiondo, M. S., & Kryscio, R. J. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm085 · Cited by 163 · see citing works
Role of the neuropathology of Alzheimer disease in dementia in the oldest-old
Haroutunian, V., Schnaider-Beeri, M., Schmeidler, J., Wysocki, M., Purohit, D. P., Perl, D. P., Libow, L. S., Lesser, G. T., Maroukian, M., & Grossman, H. T. (2008) · Archives of Neurology · doi:10.1001/archneur.65.9.1211 · Cited by 154 · see citing works
Beach, T. G., Kuo, Y., Spiegel, K., Emmerling, M. R., Sue, L. I., Kokjohn, K., & Roher, A. E. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.4.308 · Cited by 152 · see citing works
Soetanto, A., Wilson, R. S., Talbot, K., Un, A., Schneider, J. A., Sobiesk, M., Kelly, J., Leurgans, S., Bennett, D. A., & Arnold, S. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.48 · Cited by 148 · see citing works
Self-citationNeuropathologic Studies of the Baltimore Longitudinal Study of Aging (BLSA)
O'Brien, R. J., Resnick, S. M., Zonderman, A. B., Ferrucci, L., Crain, B. J., Pletnikova, O., Rudow, G., Iacono, D., Riudavets, M. A., Driscoll, I., et al. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1179 · Cited by 137 · see citing works
Oxidatively modified nucleic acids in preclinical Alzheimer's disease (PCAD) brain
Lovell, M. A., Soman, S., & Bradley, M. A. (2011) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2011.08.003 · Cited by 124 · see citing works
Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons
Riudavets, M. A., Iacono, D., Resnick, S. M., O’Brien, R., Zonderman, A. B., Martin, L. J., Rudow, G., Pletnikova, O., & Troncoso, J. C. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.05.005 · Cited by 106 · see citing works
Ganna Lyubartseva, A., Smith, J. L., Markesbery, W. R., & Lovell, M. A. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00283.x · Cited by 103 · see citing works
Dendritic pathology in Alzheimer's disease
Balogiannis, S. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.02.370 · Cited by 99 · see citing works
Religious Orders Study: Overview and Change in Cognitive and Motor Speed
Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Aging Neuropsychology and Cognition · doi:10.1080/13825580490511125 · Cited by 87 · see citing works
Self-citationNovel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment
Mitchell, T. W., Nissanov, J., Han, L.-Y., Mufson, E. J., Schneider, J. A., Cochran, E. J., Bennett, D. A., Lee, V. M.-Y., Trojanowski, J. Q., & Arnold, S. E. (2000) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540004801206 · Cited by 78 · see citing works
Self-citationA quantitative histological study of early clinical and preclinical Alzheimer's disease
Hubbard, B. M., FENTONM, G. W., & Anderson, J. M. (1990) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1990.tb00940.x · Cited by 75 · see citing works
Proteomic analysis of Waldenstrom macroglobulinemia
Hatjiharissi, E., Ngo, H., Leontovich, A. A., Leleu, X., Timm, M., Melhem, M., George, D., Lu, G., Ghobrial, J., Alsayed, Y., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3089 · Cited by 61 · see citing works
Tyrosine Phosphorylation of Tau by the Src Family Kinases Lck and Fyn
Scales, T. M. E., Derkinderen, P., Leung, K., Byers, H. L., Ward, M. A., Price, C., Bird, I. N., Perera, T. P. S., Kellie, S., Williamson, R., et al. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-12 · Cited by 55 · see citing works
Anderson, K. (2003) · Brain · doi:10.1093/brain/awg208 · Cited by 51 · see citing works
Postmortem Indices Linking Risk Factors to Cognition
Bennett, D. A. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200607001-00009 · Cited by 46 · see citing works
Self-citationMochizuki, A., Peterson, J. W., Mufson, E. J., & Trapp, B. D. (1996) · Experimental Neurology · doi:10.1006/exnr.1996.0181 · Cited by 43 · see citing works
Ewbank, D. C., & Arnold, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejme0901965 · Cited by 22 · see citing works
Self-citationMitchell, J. C., Perkinton, M. S., Yates, D. M., Lau, K., Rogelj, B., Miller, C. C. J., & McLoughlin, D. M. (2010) · PubMed · doi:10.3233/jad-2009-1341 · Cited by 8 · see citing works
Mitchell, J. C., Perkinton, M. S., Yates, D. M., Lau, K., Rogelj, B., Miller, C. C. J., & McLoughlin, D. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1341 · Cited by 5 · see citing works
Price (1999) · doi:10.1002/1531-8249(199903)45:3
Flagged first, then by citations
1 of the 66 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Religious Orders Study and Rush Memory and Aging Project
Bennett, D. A., Buchman, A. S., Boyle, P. A., Barnes, L. L., Wilson, R. S., & Schneider, J. A. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179939 · Cited by 1,260 · see citing works
Self-citationThe Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201 · see citing works
TDP-43 is a key player in the clinical features associated with Alzheimer’s disease
Josephs, K. A., Whitwell, J. L., Weigand, S. D., Murray, M. E., Tosakulwong, N., Liesinger, A. M., Petrucelli, L., Senjem, M. L., Knopman, D. S., Boeve, B. F., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1269-z · Cited by 481 · see citing works
Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology
Perez-Nievas, B. G., Stein, T. D., Tai, H.-C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E. L., Perez, J., Marquie, M., et al. (2013) · Brain · doi:10.1093/brain/awt171 · Cited by 387 · see citing works
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360 · see citing works
Jack, C. R., Wiste, H. J., Weigand, S. D., Rocca, W. A., Knopman, D. S., Mielke, M. M., Lowe, V. J., Senjem, M. L., Gunter, J. L., Preboske, G. M., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70194-2 · Cited by 358 · see citing works
Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease
Kelly, S. C., He, B., Perez, S. E., Ginsberg, S. D., Mufson, E. J., & Counts, S. E. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0411-2 · Cited by 286 · see citing works
de Wilde, M. C., Overk, C., Sijben, J., & Masliah, E. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.12.005 · Cited by 273 · see citing works
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
Pereira, J. B., Janelidze, S., Ossenkoppele, R., Kvartsberg, H., Brinkmalm, A., Mattsson, N., Stomrud, E., Smith, R. A., Zetterberg, H., Blennow, K., et al. (2020) · Brain · doi:10.1093/brain/awaa395 · Cited by 201 · see citing works
Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease
James, B. D., & Bennett, D. A. (2019) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-040218-043758 · Cited by 200 · see citing works
Self-citationBamidis, P. D., Fissler, P., Papageorgiou, S. G., Zilidou, V. I., Konstantinidis, E. I., Billis, A. S., Romanopoulou, E. D., Karagianni, M. A., Beratis, I., Tsapanou, A., et al. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00152 · Cited by 186 · see citing works
Role of Prenatal Hypoxia in Brain Development, Cognitive Functions, and Neurodegeneration
Nalivaeva, N. N., Turner, A. J., & Zhuravin, I. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00825 · Cited by 181 · see citing works
Novelty Interventions to Enhance Broad Cognitive Abilities and Prevent Dementia
Fissler, P., Küster, O. C., Schlee, W., & Kolassa, I. (2013) · Progress in brain research · doi:10.1016/b978-0-444-63327-9.00017-5 · Cited by 174 · see citing works
Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology
Shulman, J. M., Chen, K., Keenan, B. T., Chibnik, L. B., Fleisher, A., Thiyyagura, P., Roontiva, A., Aubin, C., Patsopoulos, N. A., Corneveaux, J. J., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2815 · Cited by 156 · see citing works
Self-citationZeineh, M. M., Chen, Y., Kitzler, H. H., Hammond, R., Vogel, H., & Rutt, B. K. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.022 · Cited by 151 · see citing works
Recent update on the heterogeneity of the Alzheimer’s disease spectrum
Jellinger, K. A. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02449-2 · Cited by 150 · see citing works
Socio-emotional and cognitive resilience in children with reading disabilities
Haft, S. L., Myers, C. A., & Hoeft, F. (2016) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.06.005 · Cited by 145 · see citing works
Cognitive and social lifestyle: links with neuropathology and cognition in late life
Bennett, D. A., Arnold, S. E., Valenzuela, M., Brayne, C., & Schneider, J. A. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1226-2 · Cited by 141 · see citing works
Self-citationCognitive Resilience to Psychological Stress in Military Personnel
Flood, A. P., & Keegan, R. J. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.809003 · Cited by 134 · see citing works
Molecular and cellular pathophysiology of preclinical Alzheimer’s disease
Mufson, E. J., Ikonomović, M. D., Counts, S., Perez, S. E., Malek‐Ahmadi, M. H., Scheff, S. W., & Ginsberg, S. D. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.030 · Cited by 129 · see citing works
Alzheimer's disease: The next frontier—Special Report 2017
Karlawish, J. H., Jack, C. R., Rocca, W. A., Snyder, H. M., & Carrillo, M. C. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.006 · Cited by 114 · see citing works
White, C. C., Yang, H.-S., Yu, L., Chibnik, L. B., Dawe, R., Yang, J.-Y., Klein, H.-U., Felsky, D., Ramos-Miguel, A., Arfanakis, K., et al. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002287 · Cited by 105 · see citing works
Self-citationSilva, A. R. T., Santos, A. C. F., Farfel, J. M., Grinberg, L. T., Ferretti, R. E. L., Campos, A. H. J. F. M., Cunha, I. W., Begnami, M. D., Rocha, R. M., Carraro, D. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099897 · Cited by 99 · see citing works
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes
Gómez-Isla, T., & Frosch, M. P. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00642-9 · Cited by 96 · see citing works
Effects of Prenatal Hypoxia on Nervous System Development and Related Diseases
Wang, B., Zeng, H., Liu, J., & Sun, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.755554 · Cited by 93 · see citing works
Emerging pathways driving early synaptic pathology in Alzheimer's disease
Briggs, C. A., Chakroborty, S., & Stutzmann, G. E. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.088 · Cited by 91 · see citing works
Neuropathological approaches to cerebral aging and neuroplasticity
Jellinger, K. A., & Attems, J. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.1/kjellinger · Cited by 90 · see citing works
Sex-specific effects of microglial activation on Alzheimer’s disease proteinopathy in older adults
Casaletto, K. B., Nichols, E. L., Aslanyan, V., Simone, S. M., Rabin, J. S., Joie, R. L., Brickman, A. M., Dams-O’Connor, K., Palta, P., Kumar, R. G., et al. (2022) · Brain · doi:10.1093/brain/awac257 · Cited by 87 · see citing works
Self-citationDendritic Spines: Mediators of Cognitive Resilience in Aging and Alzheimer’s Disease
Walker, C. K., & Herskowitz, J. H. (2021) · The Neuroscientist · doi:10.1177/1073858420945964 · Cited by 86 · see citing works
de Vries, L. E., Huitinga, I., Kessels, H. W. H. G., Swaab, D. F., & Verhaagen, J. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00719-7 · Cited by 82 · see citing works
Carlyle, B. C., Kandigian, S. E., Kreuzer, J., Das, S., Trombetta, B. A., Kuo, Y., Bennett, D. A., Schneider, J. A., Petyuk, V. A., Kitchen, R. R., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.012 · Cited by 65 · see citing works
Self-citationSynaptophysin and Synaptojanin-1 in Down Syndrome are Differentially Affected by Alzheimer's Disease
Martin, S. B., Dowling, A. L. S., Lianekhammy, J., Lott, I. T., Doran, E., Murphy, M. P., Beckett, T. L., Schmitt, F. A., & Head, E. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140795 · Cited by 64 · see citing works
Complement-mediated synapse loss in Alzheimer’s disease: mechanisms and involvement of risk factors
Wen, L., Bi, D., & Shen, Y. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.11.010 · Cited by 62 · see citing works
Frontal Cortex Epigenetic Dysregulation During the Progression of Alzheimer’s Disease
Mahady, L. J., Nadeem, M., Malek‐Ahmadi, M. H., Chen, K., Perez, S. E., & Mufson, E. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171032 · Cited by 60 · see citing works
Tau neurotoxicity and rescue in animal models of human Tauopathies
Krüger, L., & Mandelkow, E. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.09.004 · Cited by 60 · see citing works
Maggio, N., & Vlachos, A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.041 · Cited by 57 · see citing works
Hippocampal Transcriptomic Profiles: Subfield Vulnerability to Age and Cognitive Impairment
Ianov, L., Both, M. D. D., Chawla, M. K., Rani, A., Kennedy, A. J., Piras, I. S., Day, J. J., Siniard, A. L., Kumar, A., Sweatt, J. D., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00383 · Cited by 55 · see citing works
Late‐life physical activity relates to brain tissue synaptic integrity markers in older adults
Casaletto, K., Ramos‐Miguel, A., VandeBunte, A., Memel, M., Buchman, A., Bennett, D., & Honer, W. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12530 · Cited by 53 · see citing works
Self-citationSynaptic Compensatory Plasticity in Alzheimer’s Disease
Bhembre, N., Bonthron, C., & Opazo, P. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.0379-23.2023 · Cited by 39 · see citing works
Geerts, H., Wikswo, J. P., van der Graaf, P. H., Bai, J. P. F., Gaiteri, C., Bennett, D. A., Swalley, S. E., Schuck, E. L., Kaddurah‐Daouk, R., Tsaioun, K., et al. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12478 · Cited by 49 · see citing works
Self-citationYu, Q., Du, F., Douglas, J. T., Yu, H., Yan, S. S., & Yan, S. F. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170283 · Cited by 50 · see citing works
Correlation of Cognitive Resilience, Cognitive Flexibility and Impulsivity in Attempted Suicide
Ram, D., Chandran, S., Sadar, A., & Gowdappa, B. (2019) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_189_18 · Cited by 53 · see citing works
Zolochevska, O., & Taglialatela, G. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160518142110 · Cited by 49 · see citing works
Hampel, H., Lista, S., Néri, C., & Vergallo, A. (2019) · Progress in neurobiology · doi:10.1016/j.pneurobio.2019.101662 · Cited by 50 · see citing works
Pettigrew, C. A., Soldan, A., Zhu, Y., Cai, Q., Wang, M., Moghekar, A., Miller, M. I., Singh, B., Martinez, O., Fletcher, E. M., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.12.003 · Cited by 47 · see citing works
Perez, S. E., He, B., Nadeem, M., Wuu, J., Scheff, S. W., Abrahamson, E. E., Ikonomović, M. D., & Mufson, E. J. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.016 · Cited by 47 · see citing works
Cognitive Reserve from the Perspective of Preclinical Alzheimer Disease
Soldan, A., Pettigrew, C. A., & Albert, M. (2019) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.11.006 · Cited by 46 · see citing works
Xue, D., Li, P. W. C., Yu, D. S. F., & Lin, R. S. Y. (2023) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2023.104592 · Cited by 46 · see citing works
Strehl, A., Lenz, M., Itsekson-Hayosh, Z., Becker, D., Chapman, J., Deller, T., Maggio, N., & Vlachos, A. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.033 · Cited by 42 · see citing works
Sekiya, M., Wang, M., Fujisaki, N., Sakakibara, Y., Quan, X., Ehrlich, M. E., De Jager, P. L., Bennett, D. A., Schadt, E. E., Gandy, S., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0530-9 · Cited by 38 · see citing works
Self-citationHuang, Z., Merrihew, G. E., Larson, E. B., Park, J., Plubell, D., Fox, E. J., Montine, K. S., Latimer, C. S., Dirk Keene, C., Zou, J. Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38376-x · Cited by 37 · see citing works
Takahashi, A., Watanabe, T., Fujita, T., Hasegawa, T., SAITO, M., & Suganuma, M. (2014) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2014.921553 · Cited by 34 · see citing works
Zafar, S., Shafiq, M., Younas, N., Schmitz, M., Ferrer, I., & Zerr, I. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170237 · Cited by 31 · see citing works
Well-Being and Cognitive Resilience to Dementia-Related Neuropathology
Willroth, E. C., James, B. D., Graham, E. K., Kapasi, A., Bennett, D. A., & Mroczek, D. K. (2022) · Psychological Science · doi:10.1177/09567976221119828 · Cited by 31 · see citing works
Self-citationde Vries, L. E., Jongejan, A., Fortes, J. M., Balesar, R. A., Rozemüller, A. J. M., Moerland, P. D., Huitinga, I., Swaab, D. F., & Verhaagen, J. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01760-9 · Cited by 28 · see citing works
Datta, A., Chai, Y. L., Tan, J. M., Lee, J. H., Francis, P. T., Chen, C., Sze, S. K., & Lai, M. K. P. (2017) · Molecular Brain · doi:10.1186/s13041-017-0316-9 · Cited by 28 · see citing works
Cognitive resilience in Alzheimer’s disease: Mechanism and potential clinical intervention
Jia, B., Xu, Y., & Zhu, X. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102711 · Cited by 27 · see citing works
The interplay between age at menopause and synaptic integrity on Alzheimer’s disease risk in women
Alexander, M. W., Honer, W. G., Saloner, R., Galea, L. A. M., Bennett, D. A., Rabin, J. S., & Casaletto, K. B. (2025) · Science Advances · doi:10.1126/sciadv.adt0757 · Cited by 31 · see citing works
Self-citationThe transcriptional landscape of Alzheimer’s disease and its association with Wnt signaling pathway
Martínez, M., & Inestrosa, N. C. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.029 · Cited by 25 · see citing works
Branch, A., Monasterio, A. H., Blair, G. A., Knierim, J. J., Gallagher, M., & Haberman, R. P. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.12.015 · Cited by 26 · see citing works
Whole genome deconvolution unveils Alzheimer’s resilient epigenetic signature
Berson, E., Sreenivas, A., Phongpreecha, T., Perna, A., Grandi, F., Xue, L., Ravindra, N. G., Payrovnaziri, N., Mataraso, S. J., Kim, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40611-4 · Cited by 23 · see citing works
Cerebrospinal Fluid and Brain Proteoforms of the Granin Neuropeptide Family in Alzheimer’s Disease
Quinn, J. P., Ethier, E. C., Novielli, A., Malone, A., Ramirez, C. E., Salloum, L., Trombetta, B. A., Kivisäkk, P., Bremang, M., Selzer, S., et al. (2023) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.2c00341 · Cited by 20 · see citing works
Self-citationBriggs, C. A., Schneider, C., Richardson, J. C., & Stutzmann, G. E. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.013 · Cited by 24 · see citing works
Novel approaches to increase synaptic resilience as potential treatments for Alzheimer’s disease
Pham, A. Q., & Dore, K. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.03.032 · Cited by 21 · see citing works
Prescott, J. W., Doraiswamy, P. M., Gamberger, D., Benzinger, T. L. S., Petrella, J. R., & for the Dominantly Inherited Alzheimer Network (2021) · Radiology · doi:10.1148/radiol.2021210383 · Cited by 20 · see citing works
Koh, M. T., Branch, A., Haberman, R. P., & Gallagher, M. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.02.019 · Cited by 18 · see citing works
Cortical proteins may provide motor resilience in older adults
Buchman, A. S., Yu, L., Oveisgharan, S., Petyuk, V., Tasaki, S., Gaiteri, C., Wilson, R. S., Grodstein, F., Schneider, J. A., Klein, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90859-3 · Cited by 18 · see citing works
Self-citationMorgan, G. R., & Carlyle, B. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-57104-z · Cited by 17 · see citing works
Challenges in the Neuropathological Diagnosis of Dementias
Jellinger, K. A. (2012) · International Journal of Neuropathology · doi:10.7726/ijn.2013.1002 · Cited by 15 · see citing works
Telpoukhovskaia, M. A., Hadad, N., Gurdon, B., Dai, Y.-C., Ouellette, A. R., Neuner, S., Dunn, A. R., Willcox, J. A. L., Wu, Y.-Y., Dumitrescu, L., et al. (2023) · bioRxiv · doi:10.1101/2022.04.12.487877 · Cited by 10 · see citing works
Tripartite Relationship Among Synaptic, Amyloid, and Tau Proteins
Casaletto, K. B., Zetterberg, H., Blennow, K., Brinkmalm, A., Honer, W. G., Schneider, J. A., Bennett, D. A., Djukic, N. A., You, M. Y., Weiner‐Light, S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012145 · Cited by 14 · see citing works
Self-citationUnderstanding the molecular basis of resilience to Alzheimer’s disease
Montine, K., Berson, E., Phongpreecha, T., Huang, Z., Aghaeepour, N., Zou, J. Y., MacCoss, M., & Montine, T. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1311157 · Cited by 12 · see citing works
Proteomic Insight Into Alzheimer's Disease Pathogenesis Pathways
Ryu, T., Kim, K., Asiimwe, N., & Na, C.-H. (2025) · Proteomics · doi:10.1002/pmic.202400298 · Cited by 11 · see citing works
Proteomic clusters underlie heterogeneity in preclinical Alzheimer’s disease progression
Wisch, J. K., Butt, O. H., Gordon, B. A., Schindler, S. E., Fagan, A. M., Henson, R. L., Yang, C., Boerwinkle, A. H., Benzinger, T. L. S., Holtzman, D. M., et al. (2023) · Brain · doi:10.1093/brain/awac484 · Cited by 11 · see citing works
Seixas, A. A., Rajabli, F., Pericak‐Vance, M. A., Jean‐Louis, G., Harms, R., & Tarnanas, I. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.899080 · Cited by 11 · see citing works
Revisiting a Telencephalic Extent of the Ascending Reticular Activating System
Miyawaki, E. K., Bhattacharyya, S., & Torre, M. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01339-3 · Cited by 9 · see citing works
DNA methylation signature of a lifestyle-based resilience index for cognitive health
Zhang, W. Y., Lukacsovich, D., Young, J. I., Gomez, L., Schmidt, M. A., Martin, E. R., Kunkle, B. W., Chen, X. S., O’Shea, D. M., Galvin, J. E., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01733-7 · Cited by 11 · see citing works
Self-citationVerpoort, B., Amado, L., Vandensteen, J., Leysen, E., Dascenco, D., Vandenbempt, J., Lemmens, I. H., Wauman, J., Vennekens, K. M., Escamilla‐Ayala, A., et al. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.04.025 · Cited by 8 · see citing works
Predicting brain amyloid load with digital and blood-based biomarkers
Chen, W., Liao, Y., Shi, X., Su, F., Kong, H., Fang, Y., Zheng, Y., Zhou, J., Liu, G., Zhou, X., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01801-y · Cited by 8 · see citing works
Molecular mechanisms of aging in the pathogenesis of Alzheimer’s disease
Kakkar, A., Singh, H., Singh, B. K., Chauhan, K., Chopra, S., Chopra, H., & Mishra, A. K. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00243-y · Cited by 9 · see citing works
Saloner, R., Fonseca, C. S., Paolillo, E. W., Asken, B. M., Djukic, N. A., Lee, S. Y., Nilsson, J., Brinkmalm, A., Blennow, K., Zetterberg, H., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201165 · Cited by 8 · see citing works
Hrynchak, M. V., Rierola, M., Golovyashkina, N., Penazzi, L., Pump, W. C., David, B., Sündermann, F., Brandt, R., & Bakota, L. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00016 · Cited by 7 · see citing works
Step, K., Leal, T. P., Waldo, E., Madula, L., Swart, Y., Hernández, C. F., Kim, J. J., Bandrés‐Ciga, S., (GP2), G. P. G. P., Mata, I. F., et al. (2025) · medRxiv · doi:10.1101/2025.08.01.25331910 · Cited by 7 · see citing works
Counts, S., Beck, J. S., Maloney, B., Malek‐Ahmadi, M. H., Ginsberg, S. D., Mufson, E. J., & Lahiri, D. K. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70019 · Cited by 5 · see citing works
Brichko, R., Soldan, A., Zhu, Y., Wang, M., Faria, A. V., Albert, M., & Pettigrew, C. A. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.859826 · Cited by 6 · see citing works
Pan, W., Teng, Y., Han, X., Liu, S., Pang, X., Wang, L., & Zhao, M. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100193 · Cited by 5 · see citing works
Self-citationYang, Z. X., Sheng, J., Zhang, Q., Zhao, X., Song, Y., Dong, G., Zhang, R., Zhao, H., Wang, J., Pan, R., et al. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin26584 · Cited by 7 · see citing works
Sokolov, P. M., Валентиновна, Е. И., Karaulov, A. V., Sukhanova, A. V., & Nabiev, I. R. (2024) · Biosensors · doi:10.3390/bios14070353 · Cited by 5 · see citing works
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
Bennett, D. A. (2013) · Neurology · doi:10.1212/01.wnl.0000427396.91304.3d · Cited by 5 · see citing works
Self-citationWell-being and Cognitive Resilience to Dementia-related NeuropathologyPreprint
Willroth, E. C., James, B. D., Graham, E. K., Kapasi, A., Bennett, D. A., & Mroczek, D. K. (2022) · doi:10.31234/osf.io/sbh85 · Cited by 5 · see citing works
Self-citationCarlyle, B. C., Kandigian, S. E., Kreuzer, J., Das, S., Trombetta, B. A., Kuo, Y., Bennett, D. A., Schneider, J. A., Petyuk, V., Kitchen, R. R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.31.230680 · Cited by 4 · see citing works
Self-citationDirect evidence for dendritic spine compensation and regeneration in Alzheimer's disease models
Bhembre, N., Boskovic, Z., Willshaw, J. L., Castello-Waldow, T. P., Bonthron, C., Paolino, A., & Opazo, P. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70829 · Cited by 3 · see citing works
Alfateh, M., Vasconcelos, C., Choker, A. H., & Mohammadaein, H. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151774 · Cited by 3 · see citing works
Telpoukhovskaia, M. A., Murdy, T. J., Marola, O. J., Charland, K., Maclean, M., Luquez, T., Lish, A. M., Neuner, S., Dunn, A. R., Onos, K. D., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/trc2.12458 · Cited by 3 · see citing works
Molecular Targeting and Translational Research for New Therapeutic Strategies on Alzheimer's Disease
Takata, K. (2013) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.13-00219 · Cited by 3 · see citing works
Cerebral lactate metabolism and memory: Implications for Alzheimer's disease
Harris, R. A. (2017) · Scholarship@Western (Western University) · Cited by 3 · see citing works
Abbate, C., & Gallucci, A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251374319 · Cited by 2 · see citing works
Development of early biomarkers of Alzheimer's disease: A precision medicine perspective
Sarkar, S., Das, N., & Sambamurti, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00006-x · Cited by 2 · see citing works
Xue, D., Yu, D. S. F., Yue, L., Sheng, M., & Li, P. W. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251401560 · Cited by 2 · see citing works
Xue, D., Hu, Y., Zhang, R., & Li, J. (2025) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2025.105757 · Cited by 1 · see citing works
- Authors
- Arnold, S. E., Louneva, N., Cao, K., Wang, L.-S., Han, L.-Y., Wolk, D. A., Negash, S., Leurgans, S. E., Schneider, J. A., Buchman, A. S., Wilson, R. S., & Bennett, D. A.
- Affiliations
- University of Pennsylvania (US)
- Rush University (US)
- ORCID
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 34
- Issue
- 1
- Pages
- 157-168
- ISSN
- 0197-4580 (ISSN-L)
- PMC
- PMC3478410
- OpenAlex
- W2046582067
- Semantic Scholar
- 35b7b967d421550d0fbfcd374180037594e42757
- Cited by
- 123
- References
- 66
- Citations by year
- 2026: 7 · 2025: 18 · 2024: 5 · 2023: 10 · 2022: 17 · 2021: 7 · 2020: 7 · 2019: 10 · 2018: 5 · 2017: 9 · 2016: 6 · 2015: 3 · 2014: 9 · 2013: 9 · 2012: 1
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neurobiology of Aging (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG039478, R01AG15819, P30AG10161, P30AG10124)
- Marian S. Ware Alzheimer's Program/National Philanthropic Trust
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- Alzheimer's disease, cognitive resilience, synaptophysin, synaptopodin, presynaptic terminals, dendritic spines, astrocytes, glial fibrillary acidic protein, antibody microarrays, protein biomarkers, dementia, Religious Orders Study, brain aging
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition Disorders, Female, Glial Fibrillary Acidic Protein, Humans, Male, Nerve Tissue Proteins, Neurons, Phosphopyruvate Hydratase, Synapses, tau Proteins, Protein Array Analysis, Microscopy, Electron, Transmission
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-05.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-05.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review